[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center.  Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Research Reagents

Griffithsin, a Novel anti-HIV Protein with Potential Microbicidal, Therapeutic and/or Purification Utilities
Background: The National Cancer Institute (NCI) Molecular Targets Development Program (MTDP) seeks a Cooperative Research and Development Agreement (CRADA) collaborator to develop griffithsin (GRFT), a novel, potent anti-HIV protein isolated from an aqueous extract of (more...)
(Full Text)

Nanoscale Detection Macromolecules
Background: The National Cancer Institute, Center for Cancer Research Nanobiology Program seeks a research partnership to develop devices that can be used to detect and/or selectively modify biomolecules. Possible uses of the nanoprobes include detection (more...)
(Full Text)

HIV-1 Nucleocapsid-p7 Protein-Nucleic Acid Antagonists as HIV Treatment
The National Cancer Institute (NCI)-Developmental Therapeutics Program (DTP) - Screening Technologies Branch (STB, in collaboration with the NCI-Retroviral Assembly and Protein Chemistry Laboratories and the AIDS Vaccine Program), have identified several classes of lead (more...)
(Full Text)

Antisera to Detect Phosphorylated Phosphoinositide-Dependent Kinase 1 (PDK-
Background: The National Institutes of Health, National Center for Complementary and Alternative Medicine, Diabetes Unit is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize phospho-specific (more...)
(Full Text)

Molecular Probes for Identification or Isolation of Membrane Proteins
Background: The Nanobiology Program of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to obtain pre-clinical data to be used to further develop, evaluate, or commercialize (more...)
(Full Text)

Oligonucleotides Which Specifically Bind Retroviral Nucleocapsid Proteins
Background: The Retroviral Replication Lab at the National Cancer Institute is seeking statements of capability, or interest, from parties interested in collaborative research to further develop, evaluate, and/or commercialize oligonucleotides which bind retroviral nucleocapsid proteins (more...)
(Full Text)

3-D Imaging and Mass Spectrometry of Mammalian Cells
Background: The National Cancer Institute's Cell Biology Laboratory is seeking statements of capability or interest from parties interested in collaborative research and/or partnership agreements to further develop and commercialize tools for three-dimensional mapping of cells (more...)
(Full Text)

An Improved Non-Viral Gene Therapy System
Background: The National Cancer Institute's Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a tumor-specific gene therapy agent. The technology is also (more...)
(Full Text)

Biomarkers For Birt-Hogg-Dube (BHD) Syndrome And Renal Cancer
Background: The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize detection methods to screen a biomarker for (more...)
(Full Text)

Large Phage-Displayed Library Of Human Domain Antibodies (dAbs)
Background: The National Cancer Institute's Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a large phage-displayed human domain antibody (dAb) library. Technology: Monoclonal antibody (more...)
(Full Text)

High Throughput Isolation Of T Cells For The Treatment Of Metastatic Cancer
Background: The National Cancer Institute's Surgery Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize high throughput T cell isolation technology. Technology: The adoptive transfer (more...)
(Full Text)

Transgenic Mouse Model For Development Of Cancer Therapeutics
Background: The National Cancer Institute's Medical Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the thymidylate synthase transgenic mouse model. Technology: Thymidylate synthase (more...)
(Full Text)


E-MAIL SERVICE

TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 01-08-2009